Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Clinical trial NCT02864953 · TERMINATED
Trial details
- NCT number
- NCT02864953
- Sponsor
- Remedy Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-29
- Primary completion
- 2023-08-18
- Enrollment
- 535
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.